Many people struggle with Helicobacter pylori infections because standard treatments often fail to clear the bacteria. A new analysis looked at whether adding a drug called nitazoxanide to the usual three-drug mix could change that outcome. The researchers combined data from multiple studies involving 1286 participants to get a clearer picture. They compared this nitazoxanide-based triple therapy against standard triple therapy. The results showed a significant improvement in how often the infection was successfully cleared from the body. This held true whether doctors counted everyone who started the treatment or only those who finished it without stopping early. The improvement was consistent across different ways of measuring success. Patients also reported less abdominal pain and nausea, though these changes were not statistically significant. The certainty of this evidence was consistently high. However, the risk of bias in the included studies ranged from low to high. Future research should focus on the optimal duration of nitazoxanide use, resistance patterns, safety, and symptom relief.
Meta-analysis: Nitazoxanide triple therapy improves H. pylori eradication vs standard triple therapyNitazoxanide triple therapy significantly improves H. pylori cure rates compared to standard treatment
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider nitazoxanide-based triple therapy as an option for H. pylori eradication, but weigh limited safety data and variable study quality.
This systematic review and meta-analysis evaluated the efficacy of nitazoxanide-based triple therapy versus standard triple therapy for H. pylori eradication. The analysis included 1286 participants across multiple studies. The primary outcome was H. pylori eradication rate, assessed both per-protocol and intention-to-treat, with post-follow-up assessments also reported.
Key findings showed a significant improvement in eradication rates with nitazoxanide-based therapy. Per-protocol analysis yielded a risk ratio of 1.40 (95% CI: 1.19-1.56; P<0.0001), and intention-to-treat analysis showed RR=1.36 (95% CI: 1.19-1.56; P<0.0001). Post-follow-up results were consistent. Secondary outcomes of abdominal pain and nausea showed non-significant reductions (RR=0.50 and RR=0.78, respectively), but p-values were not reported.
The authors noted that risk of bias ranged from low to high across included studies. Certainty of evidence was consistently high. Safety data, including adverse events and discontinuations, were not reported. The review did not provide absolute event rates.
Practice relevance is limited by the lack of safety data and variability in study quality. Future research should focus on optimal treatment duration, resistance patterns, safety, and symptom relief. Clinicians should interpret these results cautiously, considering the potential for bias and absence of harm data.
What this means for you:
Adding nitazoxanide to standard triple therapy significantly improved H. pylori cure rates in this large review. More on Helicobacter pylori infection
Retrospective study compares antibiotic regimens for H. pylori eradication in children
Two antibiotic regimens cleared H. pylori in most children within four weeks
This retrospective observational study evaluated two antibiotic combinations for treating Helicobacter pylori infection in children aged 4 t…
A look at two common treatments found that both regimens successfully eliminated the bacteria in most children within four weeks.
Bismuth-containing quadruple therapy associated with higher H. pylori eradication rates compared to triple therapy in children
New Mix Clears Stomach Bugs Better in Children
This retrospective cohort study of 161 pediatric patients compared 14-day bismuth-containing quadruple therapy against triple therapy for He…
A four-drug plan works better than the usual three-drug plan for clearing stomach bacteria in kids.
Susceptibility-guided sequential therapy shows no superiority over empirical therapy for H. pylori eradication
Susceptibility-guided therapy did not beat standard treatment for stomach bug infections
This randomised controlled trial in 500 treatment-naive adults with H. pylori infection compared susceptibility-guided sequential therapy to…
A new trial found that testing for drug resistance before treatment did not improve cure rates compared to standard care for stomach infecti…
Bismuth quadruple therapy shows higher H. pylori eradication in pediatric patients with clarithromycin resistance
High-Level Clarithromycin Resistance May Predict Bismuth Success in H. pylori
This observational study of 4,610 pediatric patients with H. pylori infection compared bismuth quadruple therapy to triple therapy. Bismuth …
A simple blood test level may predict which H. pylori infections respond best to bismuth therapy, turning a treatment failure sign into a gu…
View Original Abstract ↓
Helicobacter pylori infections are the major cause of gastrointestinal disease, mainly chronic gastritis, peptic ulcer, and gastric carcinomas, affecting half of the population globally. Due to the emergence of antibiotic resistance, the efficacy of current standard therapies, particularly clarithromycin and metronidazole, has been reduced. Nitazoxanide (NTZ), a broad-spectrum antimicrobial drug, has shown promising efficacy against H. pylori infections. This study aims to assess the comparative efficacy and safety of NTZ-based regimens versus standard triple therapy in H. pylori infections. A comprehensive literature search was conducted across 4 databases. Eight randomized controlled trials, comprising 1286 participants, comparing NTZ-based regimens with standard triple therapy, were included. A random-effects model was used to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs). NTZ-based therapy showed significant improvement in primary outcome, which includes H. pylori eradication rate compared to standard triple therapy. In per-protocol (PP) and intention-to-treat patients, durational analysis showed significant improvement in H. pylori eradication rates (RR=1.40; 95% CI: 1.19-1.56; P <0.0001) and (RR=1.36; 95% CI: 1.19-1.56; P <0.0001), respectively. In addition, post follow-up assessment also shows significant effects in both patients per-protocol (RR= 1.40; 95% CI: 1.21-1.62; P <0.0001) and intention-to-treat (RR=1.36; 95% CI: 1.19-1.56; P <0.0001). In secondary outcomes, NTZ-based therapy showed non-significant reduction in abdominal pain (RR=0.50) and nausea (RR=0.78). Risk of bias was reported as low to high, although certainty of evidence was consistently high. Egger's test shows non-significant publication bias ( P =0.161). Future research should focus on NTZ's optimal duration, resistance pattern, safety, and symptom relief.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Linezolid Injection for Gram-Positive Infections Including Pneumonia and Skin Infections
FDA approves new antibiotic injection for serious bacterial infections
The FDA approved linezolid injection for nosocomial pneumonia, community-acquired pneumonia, complicated skin infections, and vancomycin-res…
The FDA approved linezolid injection for treating serious infections like pneumonia and skin infections caused by certain bacteria, includin…
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
Vancomycin Powder May Reduce Infections After High Risk Fractures
This meta-analysis of 3185 patients found that intrawound vancomycin powder significantly reduced postoperative infection rates (OR 0.59; 95…
A review of data suggests that using vancomycin powder in wounds may lower infection rates for patients with serious bone fractures.
Risk-adapted HLA delisting and imlifidase enable deceased-donor kidney transplantation for highly sensitized candidates
New guide helps transplant kidneys for hardest-to-match patients
This expert consensus provides a practical guideline for managing highly sensitized adult patients on the waitlist for deceased-donor kidney…
A new expert guide shows how to safely transplant kidneys into highly sensitized patients who have few options left.
Regenerative endodontic procedures may lead to unusual root morphology in immature teeth
Regenerative procedures can lead to unusual tooth root growth
This case report with literature review describes 2 immature teeth with pulp necrosis secondary to dens evaginatus treated with regenerative…
A new look at dental treatments shows that while some procedures save teeth, they can sometimes cause unexpected changes in how roots grow.
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …